PTC Therapeutics price target raised to $50 from $46 at TD Cowen

TD Cowen raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Hold rating on the shares. The firm updaed its model and corresponding estimates as its sum-of-the-part based price target goes higher.